Listed as one of the key publicly traded companies for investors to explore in the major investment theme of CRISPR gene-editing technology.

Bearish/Avoid, as the speaker states, 'I got burned from that years ago, and I'm done,' indicating a personal decision to no longer invest in the company.

A significant negative catalyst was mentioned for the stock: 'Intellia Patient died or is dying.'

A director made a substantial $1 million first-time ever open market purchase after the stock fell over 20%. The director's past successful timing on another stock (ABBV) adds to the high-conviction signal.